Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0000891293-12-000040)

Filing Details

Accession Number:: 0000891293-12-000040
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2012-06-29 19:54:19
Reporting Period:: 2012-06-27

Filing Date:: 2012-06-29
Accepted Time:: 2012-06-29 18:54:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
891293	Cell Therapeutics Inc	CTIC	Pharmaceutical Preparations (2834)	911533912

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1355850	G Daniel Eramian	3101 Western Avenue, Suite 600 Seattle WA 98121	Evp, Corporate Communications	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-06-27	27,415	$0.00	1,991,761	No	4	A	Direct
Common Stock	Disposition	2012-06-28	3,000	$0.57	1,988,761	No	4	S	Direct
Common Stock	Disposition	2012-06-28	200	$0.57	1,988,561	No	4	S	Direct
Common Stock	Disposition	2012-06-28	6,800	$0.57	1,981,761	No	4	S	Direct
Common Stock	Disposition	2012-06-28	9,731	$0.57	1,972,030	No	4	S	Direct
Common Stock	Disposition	2012-06-28	269	$0.57	1,971,761	No	4	S	Direct
Common Stock	Disposition	2012-06-28	10,000	$0.58	1,961,761	No	4	S	Direct
Common Stock	Disposition	2012-06-28	20,000	$0.58	1,941,761	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

As disclosed by CTIC in a Form 8-K filed on 12/1/11, CTIC granted a bonus opportunity to the reporting person that is payable in shares of CTIC stock upon the achievement of certain performance goals. The shares reported above on this Form 4 reflect the issuance of vested stock by CTIC pursuant to the award in connection with the achievement of the Pixantrone MAA Approval goal under the award.